Petmed Express, Inc. Q2 2027 Earnings Results Conference Call - PETMED EXPRESS INC

Financial Performance:

• Net sales declined 19.4% year-over-year to $35.8 million for Q2 2027, down from $44.4 million, driven by lower prescription sales and increased consumer promotions.
• Gross profit fell to $9.8 million (27.4% of sales) from $12.4 million (28.0% of sales), impacted by unfavorable product mix and reduced manufacturer rebates, partially offset by lower freight costs.
• General administrative expenses decreased 15.6% to $12.0 million, while advertising expenses plummeted 52.3% to $2.1 million due to the elimination of unproductive media spend.
• Net loss narrowed to $6.4 million ($0.31 per diluted share) compared to $8.5 million ($0.41 per share) in the prior year period.
• Adjusted EBITDA loss widened to $3.6 million from $2.3 million a year ago.
• Balance sheet remains strong with $11.4 million in cash and cash equivalents and zero debt as of September 30, 2026.

Guidance and Future Outlook:

• Management forecasts a multi-year effort to rebuild customer relationships and return the business to sustainable profitability and growth.
• Operating expenses are not expected to grow at the same pace as revenue as the company targets profitability at its current scale before expanding.
• Future quarters will focus on reporting specific KPIs to track progress against the new growth strategy.
• The company aims to operate the business profitably at its existing size while exploring transaction opportunities to monetize the Delray Beach headquarters and distribution center.

Business Segments and Product Lines:

• The core online pharmacy remains the primary strategic focus, with a plan to simplify the product assortment by curating food and accessories while prioritizing essential medications.
• Strategy includes expanding generics offerings to improve affordability for pet parents while creating margin opportunities.
• White-label partnerships are expanding, with a co-branded pharmacy launched with Rural King in July and a new partnership with Pet Supermarket added subsequently.
• Operational improvements include an SAP rollout, a new call center platform, and accelerated delivery times to enhance customer experience.

Market and Competitive Landscape:

• The market remains highly competitive, requiring a repositioning of the brand to clearly differentiate PetMed from rivals.
• Customer acquisition costs have decreased 32% year-over-year to $51, and 15% quarter-over-quarter, despite acquiring 41,000 new customers in Q2.
• The company leverages its 30-year heritage as a trusted pioneer in the online pet pharmacy sector.

Risks and Challenges:

• Significant challenges include declining sales trends and the difficulty of rebuilding customer loyalty in a competitive e-commerce environment.
• Forward-looking statements involve risks regarding the realization of projected profitability and growth, with actual results potentially differing materially from expectations.
• The timeline for returning to profitability is acknowledged as uncertain and dependent on a multi-year strategic execution.

Management Commentary and Tone:

• New CEO Jeff Willard, who joined six weeks ago, adopted a decisive and urgent tone focused on transformation, cost discipline, and streamlining the business.
• Leadership expressed confidence in the company's foundation, citing stabilization of operations and modernization of technology as completed prior to his tenure.
• Management emphasized a shift from growth-at-all-costs to efficiency and profitability, pledging to "fix" the core business.
• The tone reflected appreciation for the transition period leadership provided by interim CEO Leslie Campbell.

Analyst Questions and Answers:

• The transcript does not contain a recorded Q&A session; the call concluded with closing remarks from the CEO.

Other Key Points:

• The company is actively working to optimize marketing efficiency and improve website conversion rates to shorten the path from search to checkout.
• Retention of acquired customers is identified as a critical, fastest-growing lever for improving overall profitability.
• The company plans to reduce its product footprint to a tighter, curated assortment of non-pharmacy items to focus on its core pharmacy mission.